Day One Biopharmaceuticals
↗Brisbane, United States
Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. The company was founded with a specific focus on addressing the critical unmet need in pediatric oncology, where therapeutic innovation has historically lagged behind adult cancer research.
Their lead product, OJEMDA (tovorafenib), is a first-in-class, once-weekly oral Type II RAF inhibitor that received FDA accelerated approval in 2024. Beyond its flagship pediatric glioma program, Day One is expanding its portfolio into adult solid tumors through a robust pipeline of antibody-drug conjugates (ADCs) and strategic acquisitions, including the 2026 merger with Mersana Therapeutics.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$155M (2025)
Founded:2018
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$190M+
Investors:Canaan Partners, Atlas Venture, Access Industries, Viking Global Investors, Perceptive Advisors
STOCK
Exchange:NASDAQ
Ticker:DAWN
Market Cap:$1.17B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (OJEMDA)
Modalities:Small molecule, ADC
Active Trials:5
Trial Phases:Phase 1: 2 | Phase 2: 1 | Phase 3: 1 | Phase 4: 1
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Mersana Therapeutics (Acquired 2026)
Key Partnerships:Ipsen (Ex-US commercialization rights for tovorafenib), Children's Brain Tumor Network (Research collaboration)
COMPETITION
Position:Leader
Competitors:Jazz Pharmaceuticals, Kite Pharma, Relay Therapeutics, SpringWorks Therapeutics
LEADERSHIP
Key Executives:
Jeremy Bender, Ph.D. - CEO
Samuel Blackman, M.D., Ph.D. - Co-founder & Head of R&D
Scientific Founders:Julie Grant, Samuel Blackman
Board Members:Julie Grant (Chair), Jeremy Bender, John Josey, Scott Garland
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Day One Biopharmaceuticals. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.